Christian Pangratz – CEO and Managing Director
Before joining sterna, Christian was Senior Vice President of Business Development at Vectura Group plc. He also served as Non-Executive Director on the Board of Directors of Skyepharma AG and Jagotec AG, both subsidiaries of Vectura in Switzerland, and on the Board of Directors of Tianjin Kinnovata Pharmaceutical Co. Ltd., a China-based joint venture between Vectura and Tianjin KingYork Group Company Ltd.
From 2014 to 2016, Christian was Executive Vice President of Business Development, Alliance Management & Project Management at Skyepharma in Basel, Switzerland. Prior to this, he served as Chief Business Officer at Activaero, a German-American respiratory company, where he helped to grow the marketing and business development functions and played an instrumental role in the Company’s trade sale to Vectura in 2014.
From 2004 to 2011, Christian held a number of senior marketing, new product planning, project management, business development and alliance management positions at Nektar Therapeutics in San Francisco. Before moving to the United States, he gained extensive sales and marketing experience at Bayer and Pfizer across various European markets.
Christian also was an Adjunct Professor at Webster University in Vienna, Austria, where he taught a Marketing Strategy & Execution class. He earned both a bachelor’s degree in Business Administration and a master’s degree in International Business from Webster University.
Daniel Bock – Chief Scientific Officer
Daniel joined the company in early 2018 as its consulting Chief Scientific Officer. He has been in pharmaceutical R&D with a focus on inflammatory diseases for 20 years. His expertise spans from early drug discovery to clinical proof of concept and beyond.
He held R&D positions at Novartis and Revotar Biopharmaceuticals before working as an independent expert, advisor and consultant.
Marion Wencker – Chief Medical Officer
Marion joined sterna biologicals in early 2019 as Chief Medical Officer (consulting). Before joining sterna, Dr. Wencker held a number of positions in academic teaching hospitals, the pharmaceutical industry and CROs with a strong focus on respiratory diseases and plasma products.
From 2012 to 2015, Marion was Medical Director of a phase 1 research clinic for CRS in Mannheim, Germany. From 2006 to 2012, she was head of Medical and Clinical Affairs Europe for Talecris (now Grifols) where Marion built the newly established European Medical headquarter. From 2002 to 2006 Dr. Wecker was Therapeutic Area Director Respiratory for GSK in Germany.
Marion received her academic training at the department of Chemistry at the University Bonn and continued her education at the Medical Schools of the Universities of Freiburg, Innsbruck and Cape Town before she became a Fellow at the Ruhrlandklinik, Essen, a tertiary care hospital for respiratory diseases. Dr. Wencker is a board-certified internal medicine and respiratory medicine specialist.
Thomas Klaue – Chief Financial Officer
Thomas joined sterna in 2019, coming from INJEX Pharma, a medical device company specialized in needle-free injection systems.
Prior to INJEX, Thomas was CFO and Deputy CEO in several publicly listed companies including Marseille-Kliniken, a hospital operator, and Medigene, a biotechnology company developing oncology and immune therapies.
While at Medigene, he provided for the first SEDA financing (Stand By Equity Distribution Agreement) in Germany and got the company listed under the prestigious TecDAX, Germany´s top 30 Technology Companies.
Until 2006, Dr. Klaue held several senior management positions at Infineon Technologies AG, a BlueChip semiconductor firm. During his tenure, Thomas led the Corporate Venture Capital and M&A department, and became General Manager of Infineon’s global BioChip-Business which was awarded with the Wall Street Journal Innovation Award in 2003.
From 1995 until 2000, Thomas served as Vice President M&A at Daimler-Benz Aerospace, today Airbus Industries. Between 1990 and 1995, he worked for the Federal German Government as Director of Treuhandanstalt (THA) in Berlin, Germany's federal trust organization which was charge for East Germany's restructuring and integration process after the country`s reunion 1990. In this position he spearheaded the privatization of the East German Chemical and Pharmaceutical industry.
Prior to his career in industry, Thomas was Assistant Professor at the University of Mannheim in Germany and a Research Fellow at the M.I.T. Sloan School of Management in Boston. His research focused on innovation management and organizational changes in industrial corporations. Dr. Klaue completed his Master in Engineering at the University of Karlsruhe, received a Ph.D. in Business Economics from the University of Mannheim and is a Harvard Business School graduate.